US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dermata Therapeutics Inc

5.48

+0.15002.81%

Volume:13.08K

Turnover:71.11K

Market Cap:3.73M

PE:-0.13

High:5.61

Open:5.48

Low:5.30

Close:5.33

52wk High:24.90

52wk Low:5.09

Shares:681.56K

Float Shares:459.20K

Volume Ratio:0.70

T/O Rate:2.85%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-42.3158

EPS(LYR):-80.3223

ROE:-231.27%

ROA:-110.91%

PB:0.67

PE(LYR):-0.07

Loading ...

Overview Company News Filings

Dermata Therapeutics Is Maintained at Buy by Maxim Group

Dermata Therapeutics Q2 EPS $(1.66) Beats $(2.90) Estimate

Dermata Therapeutics Announces Positive Results from XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne Treatment

Dermata Therapeutics Inc trading halted, news pending

Dermata Therapeutics Announces 1:10 Reverse Stock Split Effective August 1, 2025

Dermata Therapeutics Inc. Conducted Annual Stockholders Meeting

Dermata Therapeutics receives notice of grant of Australian patent

Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment

Dermata Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Rule

Dermata Therapeutics Inc. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments

Dermata Therapeutics Inc. Appoints Baker Tilly as New Certifying Accountant Following Merger

Dermata Therapeutics Is Maintained at Buy by Maxim Group

Dermata Therapeutics Begins Manufacturing for STAR-2 Trial

BRIEF-Dermata Therapeutics Inc - Potential NDA Filing For Xyngari In H1 2028 - SEC Filing

Dermata Therapeutics Inc. Announces Initiation of Drug Manufacturing for XYNGARI™ Phase 3 STAR-2 Trial, Set to Begin in Q4 2025

Dermata Faces Nasdaq Delisting Risk Over Bid Price

Dermata Reports Positive Phase 3 Trial Results

Dermata Therapeutics Announces Positive Phase 3 Trial Results, Reports $6.6M Cash Increase in Q1 2025

Press Release: California Water Service Group Reports First Quarter 2025 Results

Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/DRMA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DRMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DRMA\",,,,,undefined,":{"symbol":"DRMA","market":"US","secType":"STK","nameCN":"Dermata Therapeutics Inc","latestPrice":5.48,"timestamp":1755892800000,"preClose":5.33,"halted":0,"volume":13078,"delay":0,"floatShares":459200,"shares":681557,"eps":-42.31578,"marketStatus":"Pre-Mkt","change":0.15,"latestTime":"08-25 07:21:59 EDT","open":5.475,"high":5.605,"low":5.3,"amount":71109.95101599999,"amplitude":0.057223,"askPrice":6.1,"askSize":20,"bidPrice":4.88,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-42.31578,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1756128600000},"marketStatusCode":1,"adr":0,"listingDate":1628827200000,"exchange":"NASDAQ","adjPreClose":5.34,"postHourTrading":{"tag":"盘后","latestPrice":5.48,"preClose":5.48,"latestTime":"19:12 EDT","volume":15,"amount":83.92,"timestamp":1755904334120},"volumeRatio":0.7010302643196982},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DRMA\",,,,,undefined,":{"symbol":"DRMA","floatShares":459200,"roa":"-110.91%","roe":"-231.27%","lyrEps":-80.322277,"volumeRatio":0.7010302643196982,"shares":681557,"dividePrice":0,"high":5.605,"amplitude":0.057223,"preClose":5.33,"low":5.3,"week52Low":5.09,"pbRate":"0.67","week52High":24.9,"institutionHeld":0,"latestPrice":5.48,"committee":0.666667,"eps":-42.31578,"divideRate":0,"volume":13078,"delay":0,"ttmEps":-42.31578,"open":5.475,"prevYearClose":13.5,"prevWeekClose":5.48,"prevMonthClose":6.232,"prevQuarterClose":5.85,"fiveDayClose":5.98,"twentyDayClose":6.992,"sixtyDayClose":7.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DRMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-13","symbol":"DRMA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-1.66},{"market":"US","date":"2025-08-01","symbol":"DRMA","defaultRemindTime":1754055000000,"type":"split","dateTimestamp":1754020800000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-05-14","symbol":"DRMA","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2025-03-17","symbol":"DRMA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"DRMA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.04}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DRMA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DRMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1668139200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DRMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DRMA","date":"2025-08-22","current":-0.351707,"percent":0.600408,"low":-13.951895,"twenty":-0.867543,"median":-0.393679,"eighty":-0.240825,"high":-0.142342,"avg":-1.253209,"sd":2.370749,"marketCap":3632698},"quantilePoints":[{"date":"2021-08-13","current":-10.344345,"twenty":-13.951895,"median":-13.951895,"eighty":-11.787365,"marketCap":42621442},{"date":"2021-08-20","current":-9.318565,"twenty":-12.640293,"median":-10.326693,"eighty":-9.726884,"marketCap":38394956},{"date":"2021-08-27","current":-10.693103,"twenty":-10.685018,"median":-10.309041,"eighty":-9.581344,"marketCap":44058420},{"date":"2021-09-03","current":-10.864921,"twenty":-11.246962,"median":-10.521287,"eighty":-9.694542,"marketCap":44766354},{"date":"2021-09-10","current":-9.237709,"twenty":-10.889178,"median":-10.357014,"eighty":-9.581344,"marketCap":38061811},{"date":"2021-09-17","current":-8.429157,"twenty":-10.830557,"median":-10.005834,"eighty":-9.25388,"marketCap":34730362},{"date":"2021-09-24","current":-10.430324,"twenty":-10.830557,"median":-10.167545,"eighty":-9.3408,"marketCap":42975699},{"date":"2021-10-01","current":-8.27393,"twenty":-10.693103,"median":-9.904967,"eighty":-8.89239,"marketCap":38311670},{"date":"2021-10-08","current":-7.770299,"twenty":-10.693103,"median":-9.712734,"eighty":-8.441285,"marketCap":35979655},{"date":"2021-10-15","current":-8.032007,"twenty":-10.68906,"median":-9.540917,"eighty":-8.115646,"marketCap":37191470},{"date":"2021-10-22","current":-7.644392,"twenty":-10.624377,"median":-9.278137,"eighty":-8.024093,"marketCap":35396652},{"date":"2021-10-29","current":-8.399837,"twenty":-10.418196,"median":-9.047362,"eighty":-8.024093,"marketCap":38894674},{"date":"2021-11-05","current":-10.360399,"twenty":-10.624377,"median":-9.20549,"eighty":-8.040821,"marketCap":47972874},{"date":"2021-11-12","current":-9.10492,"twenty":-10.418196,"median":-9.209243,"eighty":-8.079672,"marketCap":42159494},{"date":"2021-11-19","current":-4.797783,"twenty":-10.367826,"median":-9.121108,"eighty":-7.899804,"marketCap":27567745},{"date":"2021-11-26","current":-3.913599,"twenty":-10.360399,"median":-9.065349,"eighty":-7.770299,"marketCap":22487284},{"date":"2021-12-03","current":-3.319312,"twenty":-10.344345,"median":-8.752578,"eighty":-7.644392,"marketCap":19072548},{"date":"2021-12-10","current":-3.348302,"twenty":-10.342412,"median":-8.516765,"eighty":-7.087964,"marketCap":19239121},{"date":"2021-12-17","current":-3.478755,"twenty":-10.309041,"median":-8.399837,"eighty":-4.536877,"marketCap":19988697},{"date":"2021-12-23","current":-3.0729,"twenty":-10.244357,"median":-8.27393,"eighty":-3.867216,"marketCap":17656682},{"date":"2021-12-31","current":-2.522097,"twenty":-10.161283,"median":-8.157015,"eighty":-3.545431,"marketCap":14491805},{"date":"2022-01-07","current":-2.275686,"twenty":-10.130167,"median":-8.094062,"eighty":-3.490351,"marketCap":13075939},{"date":"2022-01-14","current":-2.246696,"twenty":-10.110836,"median":-8.027061,"eighty":-3.348302,"marketCap":12909367},{"date":"2022-01-21","current":-2.377149,"twenty":-10.046262,"median":-7.905201,"eighty":-3.232343,"marketCap":13658943},{"date":"2022-01-28","current":-2.956942,"twenty":-9.945314,"median":-7.806273,"eighty":-2.951144,"marketCap":16990392},{"date":"2022-02-04","current":-3.217848,"twenty":-9.88059,"median":-7.725332,"eighty":-3.026517,"marketCap":18489545},{"date":"2022-02-11","current":-1.652409,"twenty":-9.85221,"median":-7.644392,"eighty":-2.838084,"marketCap":9494631},{"date":"2022-02-18","current":-1.782862,"twenty":-9.686456,"median":-7.357448,"eighty":-2.516299,"marketCap":10244207},{"date":"2022-02-25","current":-1.797357,"twenty":-9.581344,"median":-7.022737,"eighty":-2.484411,"marketCap":10327493},{"date":"2022-03-04","current":-1.579935,"twenty":-9.565173,"median":-4.797783,"eighty":-2.368453,"marketCap":9078200},{"date":"2022-03-11","current":-1.348018,"twenty":-9.496447,"median":-4.007815,"eighty":-2.252494,"marketCap":7745620},{"date":"2022-03-18","current":-1.449481,"twenty":-9.385271,"median":-3.681682,"eighty":-2.174222,"marketCap":8328624},{"date":"2022-03-25","current":-1.913315,"twenty":-9.286223,"median":-3.558477,"eighty":-2.069859,"marketCap":10993783},{"date":"2022-04-01","current":-1.349025,"twenty":-9.226323,"median":-3.52224,"eighty":-1.837942,"marketCap":10660638},{"date":"2022-04-08","current":-1.237309,"twenty":-9.194854,"median":-3.486003,"eighty":-1.78866,"marketCap":9777804},{"date":"2022-04-14","current":-1.206745,"twenty":-9.166075,"median":-3.413528,"eighty":-1.753901,"marketCap":9536274},{"date":"2022-04-22","current":-1.338486,"twenty":-9.130821,"median":-3.348302,"eighty":-1.710388,"marketCap":10577352},{"date":"2022-04-29","current":-1.202663,"twenty":-9.100603,"median":-3.290323,"eighty":-1.658207,"marketCap":9504016},{"date":"2022-05-06","current":-1.039194,"twenty":-9.076141,"median":-3.217848,"eighty":-1.520216,"marketCap":8212208},{"date":"2022-05-13","current":-0.96213,"twenty":-9.008619,"median":-3.174364,"eighty":-1.449481,"marketCap":7603212},{"date":"2022-05-20","current":-0.770426,"twenty":-8.833433,"median":-3.0729,"eighty":-1.38195,"marketCap":6459040},{"date":"2022-05-27","current":-0.864198,"twenty":-8.745907,"median":-2.913457,"eighty":-1.355935,"marketCap":7245197},{"date":"2022-06-03","current":-0.757769,"twenty":-8.719225,"median":-2.833736,"eighty":-1.349025,"marketCap":6352927},{"date":"2022-06-10","current":-0.649359,"twenty":-8.543732,"median":-2.696035,"eighty":-1.331103,"marketCap":5444048},{"date":"2022-06-17","current":-0.532144,"twenty":-8.489799,"median":-2.507603,"eighty":-1.243632,"marketCap":4461351},{"date":"2022-06-24","current":-0.528292,"twenty":-8.441285,"median":-2.485861,"eighty":-1.23031,"marketCap":4429056},{"date":"2022-07-01","current":-0.564612,"twenty":-8.405701,"median":-2.391644,"eighty":-1.205372,"marketCap":4733553},{"date":"2022-07-08","current":-0.878836,"twenty":-8.356669,"median":-2.362655,"eighty":-1.192609,"marketCap":7367919},{"date":"2022-07-15","current":-0.81445,"twenty":-8.295514,"median":-2.268439,"eighty":-1.046129,"marketCap":6828118},{"date":"2022-07-22","current":-0.77626,"twenty":-8.209177,"median":-2.188717,"eighty":-0.900663,"marketCap":6507944},{"date":"2022-07-29","current":-0.639674,"twenty":-8.166009,"median":-2.174222,"eighty":-0.869261,"marketCap":5362848},{"date":"2022-08-05","current":-0.682488,"twenty":-8.155217,"median":-2.101748,"eighty":-0.858501,"marketCap":5721786},{"date":"2022-08-12","current":-0.726402,"twenty":-8.13723,"median":-2.022026,"eighty":-0.824753,"marketCap":6089952},{"date":"2022-08-19","current":-0.75014,"twenty":-8.108451,"median":-1.855336,"eighty":-0.814451,"marketCap":7338243},{"date":"2022-08-26","current":-0.658128,"twenty":-8.08327,"median":-1.804604,"eighty":-0.773926,"marketCap":6438137},{"date":"2022-09-02","current":-0.627251,"twenty":-8.049634,"median":-1.782862,"eighty":-0.769003,"marketCap":6136081},{"date":"2022-09-09","current":-0.743531,"twenty":-8.02805,"median":-1.754017,"eighty":-0.759508,"marketCap":7273589},{"date":"2022-09-16","current":-0.641295,"twenty":-7.978946,"median":-1.739377,"eighty":-0.753192,"marketCap":6273471},{"date":"2022-09-23","current":-0.557648,"twenty":-7.906999,"median":-1.710388,"eighty":-0.739857,"marketCap":5455192},{"date":"2022-09-30","current":-0.537098,"twenty":-7.874623,"median":-1.688646,"eighty":-0.730443,"marketCap":5254158},{"date":"2022-10-07","current":-0.61713,"twenty":-7.827857,"median":-1.616172,"eighty":-0.724116,"marketCap":6037079},{"date":"2022-10-14","current":-0.733204,"twenty":-7.791883,"median":-1.53174,"eighty":-0.717793,"marketCap":7172567},{"date":"2022-10-21","current":-0.673308,"twenty":-7.763104,"median":-1.478471,"eighty":-0.707208,"marketCap":6586639},{"date":"2022-10-28","current":-0.71508,"twenty":-7.730728,"median":-1.445755,"eighty":-0.712892,"marketCap":6995273},{"date":"2022-11-04","current":-0.660916,"twenty":-7.691157,"median":-1.401721,"eighty":-0.70428,"marketCap":6465413},{"date":"2022-11-11","current":-0.738184,"twenty":-7.665976,"median":-1.364569,"eighty":-0.699559,"marketCap":7746623},{"date":"2022-11-18","current":-0.813028,"twenty":-7.622808,"median":-1.355555,"eighty":-0.702636,"marketCap":8532056},{"date":"2022-11-25","current":-0.72847,"twenty":-7.583236,"median":-1.349025,"eighty":-0.703461,"marketCap":7644686},{"date":"2022-12-02","current":-0.73876,"twenty":-7.475653,"median":-1.348521,"eighty":-0.70428,"marketCap":7752674},{"date":"2022-12-09","current":-0.21577,"twenty":-7.145943,"median":-1.331103,"eighty":-0.697287,"marketCap":2264323},{"date":"2022-12-16","current":-0.260746,"twenty":-7.061873,"median":-1.288424,"eighty":-0.682166,"marketCap":2736309},{"date":"2022-12-23","current":-0.209773,"twenty":-6.940116,"median":-1.237309,"eighty":-0.673955,"marketCap":2201391},{"date":"2022-12-30","current":-0.471672,"twenty":-6.870541,"median":-1.231854,"eighty":-0.668874,"marketCap":4949803},{"date":"2023-01-06","current":-0.346495,"twenty":-5.212335,"median":-1.222554,"eighty":-0.657739,"marketCap":3636174},{"date":"2023-01-13","current":-0.320076,"twenty":-4.589058,"median":-1.204356,"eighty":-0.644925,"marketCap":3358933},{"date":"2023-01-20","current":-0.339096,"twenty":-4.258576,"median":-1.202069,"eighty":-0.640027,"marketCap":3558535},{"date":"2023-01-27","current":-0.387473,"twenty":-3.99477,"median":-1.167634,"eighty":-0.627309,"marketCap":4066207},{"date":"2023-02-03","current":-0.355653,"twenty":-3.925195,"median":-1.044973,"eighty":-0.619857,"marketCap":3732285},{"date":"2023-02-10","current":-0.32853,"twenty":-3.774449,"median":-0.96213,"eighty":-0.615562,"marketCap":3447650},{"date":"2023-02-17","current":-0.339802,"twenty":-3.672986,"median":-0.894537,"eighty":-0.608144,"marketCap":3565940},{"date":"2023-02-24","current":-0.346158,"twenty":-3.626602,"median":-0.874158,"eighty":-0.598929,"marketCap":3326896},{"date":"2023-03-03","current":-0.352569,"twenty":-3.559926,"median":-0.868379,"eighty":-0.585445,"marketCap":3388506},{"date":"2023-03-10","current":-0.299106,"twenty":-3.539633,"median":-0.858453,"eighty":-0.568157,"marketCap":2874685},{"date":"2023-03-17","current":-0.14263,"twenty":-3.52224,"median":-0.847625,"eighty":-0.558893,"marketCap":1370804},{"date":"2023-03-24","current":-0.382678,"twenty":-3.516442,"median":-0.826007,"eighty":-0.541889,"marketCap":3677886},{"date":"2023-03-31","current":-0.320555,"twenty":-3.501947,"median":-0.818853,"eighty":-0.529833,"marketCap":3080827},{"date":"2023-04-06","current":-0.295706,"twenty":-3.490351,"median":-0.814451,"eighty":-0.428308,"marketCap":2842003},{"date":"2023-04-14","current":-0.288251,"twenty":-3.472957,"median":-0.808704,"eighty":-0.383637,"marketCap":2770356},{"date":"2023-04-21","current":-0.710688,"twenty":-3.435271,"median":-0.789964,"eighty":-0.383637,"marketCap":6830360},{"date":"2023-04-28","current":-0.429892,"twenty":-3.377291,"median":-0.784631,"eighty":-0.387473,"marketCap":4131651},{"date":"2023-05-03","current":-0.372738,"twenty":-3.377291,"median":-0.782256,"eighty":-0.384596,"marketCap":3582357},{"date":"2023-05-12","current":-0.47959,"twenty":-3.365695,"median":-0.771545,"eighty":-0.387473,"marketCap":4609299},{"date":"2023-05-19","current":-0.648111,"twenty":-3.348302,"median":-0.770426,"eighty":-0.389531,"marketCap":5875065},{"date":"2023-05-26","current":-0.492653,"twenty":-3.342504,"median":-0.766869,"eighty":-0.393115,"marketCap":4465853},{"date":"2023-06-02","current":-0.478448,"twenty":-3.319312,"median":-0.75964,"eighty":-0.395103,"marketCap":4337086},{"date":"2023-06-09","current":-0.671938,"twenty":-3.261333,"median":-0.75922,"eighty":-0.4038,"marketCap":6091054},{"date":"2023-06-16","current":-0.65083,"twenty":-3.261333,"median":-0.751172,"eighty":-0.417467,"marketCap":5899712},{"date":"2023-06-23","current":-0.701841,"twenty":-3.226545,"median":-0.749417,"eighty":-0.417467,"marketCap":6362122},{"date":"2023-06-30","current":-0.605096,"twenty":-3.217848,"median":-0.743634,"eighty":-0.423431,"marketCap":5485138},{"date":"2023-07-07","current":-0.566398,"twenty":-3.206252,"median":-0.742797,"eighty":-0.428401,"marketCap":5134344},{"date":"2023-07-14","current":-0.576952,"twenty":-3.177263,"median":-0.738126,"eighty":-0.429892,"marketCap":5230015},{"date":"2023-07-21","current":-0.534736,"twenty":-3.136677,"median":-0.736307,"eighty":-0.434862,"marketCap":4847331},{"date":"2023-07-28","current":-0.496038,"twenty":-3.090294,"median":-0.733359,"eighty":-0.454058,"marketCap":4496537},{"date":"2023-08-04","current":-0.43975,"twenty":-3.026517,"median":-0.728603,"eighty":-0.444104,"marketCap":3986292},{"date":"2023-08-11","current":-0.408088,"twenty":-2.951144,"median":-0.728144,"eighty":-0.428401,"marketCap":3699279},{"date":"2023-08-18","current":-0.484167,"twenty":-2.919255,"median":-0.725975,"eighty":-0.429892,"marketCap":3890621},{"date":"2023-08-25","current":-0.440513,"twenty":-2.872872,"median":-0.722826,"eighty":-0.433835,"marketCap":3539827},{"date":"2023-09-01","current":-0.492105,"twenty":-2.838084,"median":-0.720771,"eighty":-0.430966,"marketCap":3954402},{"date":"2023-09-08","current":-0.464324,"twenty":-2.7946,"median":-0.715506,"eighty":-0.432576,"marketCap":3731169},{"date":"2023-09-15","current":-0.445156,"twenty":-2.719227,"median":-0.713219,"eighty":-0.43337,"marketCap":3577139},{"date":"2023-09-22","current":-0.428607,"twenty":-2.661247,"median":-0.709968,"eighty":-0.43337,"marketCap":3444156},{"date":"2023-09-29","current":-0.428607,"twenty":-2.519198,"median":-0.704335,"eighty":-0.429892,"marketCap":3444156},{"date":"2023-10-06","current":-0.377611,"twenty":-2.507603,"median":-0.703256,"eighty":-0.427647,"marketCap":3034365},{"date":"2023-10-13","current":-0.317725,"twenty":-2.504704,"median":-0.699812,"eighty":-0.42067,"marketCap":2553140},{"date":"2023-10-20","current":-0.273832,"twenty":-2.490209,"median":-0.693604,"eighty":-0.411831,"marketCap":2200433},{"date":"2023-10-27","current":-0.252799,"twenty":-2.484411,"median":-0.68763,"eighty":-0.410199,"marketCap":2031414},{"date":"2023-11-02","current":-0.234464,"twenty":-2.461219,"median":-0.682602,"eighty":-0.402016,"marketCap":1884081},{"date":"2023-11-10","current":-0.310343,"twenty":-2.417735,"median":-0.681828,"eighty":-0.387473,"marketCap":2493824},{"date":"2023-11-17","current":-0.302706,"twenty":-2.385846,"median":-0.678974,"eighty":-0.380484,"marketCap":2218929},{"date":"2023-11-24","current":-0.283955,"twenty":-2.37425,"median":-0.676544,"eighty":-0.37763,"marketCap":2081482},{"date":"2023-12-01","current":-0.324284,"twenty":-2.353958,"median":-0.672107,"eighty":-0.371988,"marketCap":2377105},{"date":"2023-12-08","current":-0.324371,"twenty":-2.310473,"median":-0.668874,"eighty":-0.363106,"marketCap":2377743},{"date":"2023-12-15","current":-0.334576,"twenty":-2.272787,"median":-0.659522,"eighty":-0.356054,"marketCap":2452550},{"date":"2023-12-22","current":-0.294504,"twenty":-2.258292,"median":-0.656183,"eighty":-0.352466,"marketCap":2158810},{"date":"2023-12-29","current":-0.293973,"twenty":-2.252494,"median":-0.654348,"eighty":-0.351825,"marketCap":2154917},{"date":"2024-01-05","current":-0.294456,"twenty":-2.2351,"median":-0.653941,"eighty":-0.349028,"marketCap":2158456},{"date":"2024-01-12","current":-0.258198,"twenty":-2.188717,"median":-0.65083,"eighty":-0.34403,"marketCap":1892675},{"date":"2024-01-19","current":-0.18829,"twenty":-2.188717,"median":-0.648111,"eighty":-0.340037,"marketCap":1380223},{"date":"2024-01-26","current":-0.223051,"twenty":-2.174222,"median":-0.64252,"eighty":-0.336671,"marketCap":1635033},{"date":"2024-02-02","current":-0.221023,"twenty":-2.174222,"median":-0.639674,"eighty":-0.335006,"marketCap":1620169},{"date":"2024-02-09","current":-0.212333,"twenty":-2.145232,"median":-0.63236,"eighty":-0.333176,"marketCap":1556467},{"date":"2024-02-16","current":-0.224499,"twenty":-2.101748,"median":-0.629722,"eighty":-0.330658,"marketCap":1645650},{"date":"2024-02-23","current":-0.206085,"twenty":-2.090152,"median":-0.628686,"eighty":-0.328765,"marketCap":1510668},{"date":"2024-03-01","current":-0.221602,"twenty":-2.064061,"median":-0.626254,"eighty":-0.327339,"marketCap":1624416},{"date":"2024-03-08","current":-0.377205,"twenty":-2.000284,"median":-0.620022,"eighty":-0.328158,"marketCap":2765034},{"date":"2024-03-15","current":-0.364847,"twenty":-1.92781,"median":-0.618111,"eighty":-0.328484,"marketCap":2674443},{"date":"2024-03-22","current":-0.363484,"twenty":-1.866932,"median":-0.614394,"eighty":-0.328718,"marketCap":2664451},{"date":"2024-03-28","current":-0.335918,"twenty":-1.837942,"median":-0.612132,"eighty":-0.328765,"marketCap":2618376},{"date":"2024-04-05","current":-0.353692,"twenty":-1.81765,"median":-0.609282,"eighty":-0.328765,"marketCap":2756921},{"date":"2024-04-12","current":-0.341814,"twenty":-1.803155,"median":-0.606436,"eighty":-0.329118,"marketCap":2664336},{"date":"2024-04-19","current":-0.289004,"twenty":-1.797357,"median":-0.602415,"eighty":-0.328671,"marketCap":2252696},{"date":"2024-04-26","current":-0.290627,"twenty":-1.78866,"median":-0.597741,"eighty":-0.326311,"marketCap":2265351},{"date":"2024-05-03","current":-0.290627,"twenty":-1.782862,"median":-0.591413,"eighty":-0.324336,"marketCap":2265351},{"date":"2024-05-10","current":-0.276528,"twenty":-1.765555,"median":-0.588628,"eighty":-0.321828,"marketCap":2155447},{"date":"2024-05-17","current":-0.265755,"twenty":-1.75393,"median":-0.581702,"eighty":-0.320555,"marketCap":2309091},{"date":"2024-05-24","current":-0.177764,"twenty":-1.745175,"median":-0.576952,"eighty":-0.318671,"marketCap":1544559},{"date":"2024-05-31","current":-0.185006,"twenty":-1.739377,"median":-0.576829,"eighty":-0.316483,"marketCap":1607482},{"date":"2024-06-07","current":-0.179129,"twenty":-1.727781,"median":-0.572875,"eighty":-0.3137,"marketCap":1556416},{"date":"2024-06-14","current":-0.203485,"twenty":-1.710388,"median":-0.568157,"eighty":-0.310397,"marketCap":1768040},{"date":"2024-06-21","current":-0.154635,"twenty":-1.710388,"median":-0.56589,"eighty":-0.306522,"marketCap":1343598},{"date":"2024-06-28","current":-0.150753,"twenty":-1.70459,"median":-0.564998,"eighty":-0.304679,"marketCap":1309867},{"date":"2024-07-05","current":-0.144283,"twenty":-1.695893,"median":-0.56288,"eighty":-0.302797,"marketCap":1253650},{"date":"2024-07-12","current":-0.166929,"twenty":-1.692994,"median":-0.56076,"eighty":-0.298438,"marketCap":1450411},{"date":"2024-07-15","current":-0.181894,"twenty":-1.690095,"median":-0.560061,"eighty":-0.298305,"marketCap":1580439},{"date":"2024-08-02","current":-0.197849,"twenty":-1.687196,"median":-0.559362,"eighty":-0.297987,"marketCap":1719074},{"date":"2024-08-09","current":-0.185006,"twenty":-1.664005,"median":-0.557394,"eighty":-0.294771,"marketCap":1816118},{"date":"2024-08-16","current":-0.276158,"twenty":-1.630667,"median":-0.552326,"eighty":-0.294485,"marketCap":2710920},{"date":"2024-08-23","current":-0.246666,"twenty":-1.59443,"median":-0.548632,"eighty":-0.292148,"marketCap":2421405},{"date":"2024-08-30","current":-0.230579,"twenty":-1.562541,"median":-0.541772,"eighty":-0.290627,"marketCap":2263487},{"date":"2024-09-06","current":-0.191702,"twenty":-1.535581,"median":-0.537511,"eighty":-0.28922,"marketCap":1881852},{"date":"2024-09-13","current":-0.194383,"twenty":-1.510504,"median":-0.535865,"eighty":-0.286919,"marketCap":1908172},{"date":"2024-09-20","current":-0.2346,"twenty":-1.495864,"median":-0.534736,"eighty":-0.285715,"marketCap":2302966},{"date":"2024-09-27","current":-0.207789,"twenty":-1.466875,"median":-0.530218,"eighty":-0.284026,"marketCap":2039770},{"date":"2024-10-04","current":-0.191702,"twenty":-1.449481,"median":-0.52326,"eighty":-0.283281,"marketCap":1881852},{"date":"2024-10-11","current":-0.179637,"twenty":-1.4465,"median":-0.503707,"eighty":-0.279733,"marketCap":1763414},{"date":"2024-10-18","current":-0.24307,"twenty":-1.425905,"median":-0.500042,"eighty":-0.277221,"marketCap":2386114},{"date":"2024-10-25","current":-0.212302,"twenty":-1.401721,"median":-0.493576,"eighty":-0.275851,"marketCap":2084074},{"date":"2024-10-31","current":-0.207687,"twenty":-1.396778,"median":-0.492105,"eighty":-0.271403,"marketCap":2038768},{"date":"2024-11-08","current":-0.206148,"twenty":-1.375626,"median":-0.47959,"eighty":-0.261137,"marketCap":2023666},{"date":"2024-11-15","current":-0.159321,"twenty":-1.367889,"median":-0.47558,"eighty":-0.258573,"marketCap":1795626},{"date":"2024-11-22","current":-0.208232,"twenty":-1.358718,"median":-0.471672,"eighty":-0.254498,"marketCap":2346883},{"date":"2024-11-29","current":-0.204303,"twenty":-1.357456,"median":-0.464324,"eighty":-0.252002,"marketCap":2302598},{"date":"2024-12-06","current":-0.219097,"twenty":-1.355555,"median":-0.460356,"eighty":-0.243328,"marketCap":2469329},{"date":"2024-12-13","current":-0.197368,"twenty":-1.349025,"median":-0.45734,"eighty":-0.24248,"marketCap":2224437},{"date":"2024-12-20","current":-0.190125,"twenty":-1.349025,"median":-0.450435,"eighty":-0.239963,"marketCap":2142806},{"date":"2024-12-27","current":-0.245569,"twenty":-1.349025,"median":-0.447618,"eighty":-0.239695,"marketCap":2767689},{"date":"2025-01-03","current":-0.25169,"twenty":-1.349025,"median":-0.445971,"eighty":-0.239982,"marketCap":2836667},{"date":"2025-01-10","current":-0.22815,"twenty":-1.348622,"median":-0.444482,"eighty":-0.239975,"marketCap":2571367},{"date":"2025-01-17","current":-0.240825,"twenty":-1.344205,"median":-0.440513,"eighty":-0.239975,"marketCap":2714221},{"date":"2025-01-24","current":-0.215475,"twenty":-1.337009,"median":-0.440513,"eighty":-0.237592,"marketCap":2428513},{"date":"2025-01-31","current":-0.217286,"twenty":-1.328364,"median":-0.43456,"eighty":-0.2346,"marketCap":2448921},{"date":"2025-02-07","current":-0.220907,"twenty":-1.317407,"median":-0.430591,"eighty":-0.232765,"marketCap":2489736},{"date":"2025-02-14","current":-0.204611,"twenty":-1.305814,"median":-0.42925,"eighty":-0.230669,"marketCap":2306067},{"date":"2025-02-21","current":-0.219097,"twenty":-1.259441,"median":-0.428607,"eighty":-0.230182,"marketCap":2469329},{"date":"2025-02-28","current":-0.21026,"twenty":-1.243632,"median":-0.425678,"eighty":-0.229225,"marketCap":2369739},{"date":"2025-03-07","current":-0.426882,"twenty":-1.237309,"median":-0.422654,"eighty":-0.229943,"marketCap":4811177},{"date":"2025-03-14","current":-0.416299,"twenty":-1.233093,"median":-0.425678,"eighty":-0.229961,"marketCap":4691892},{"date":"2025-03-21","current":-0.521521,"twenty":-1.231854,"median":-0.422654,"eighty":-0.229961,"marketCap":6408164},{"date":"2025-03-28","current":-0.627593,"twenty":-1.224135,"median":-0.426882,"eighty":-0.230182,"marketCap":7711520},{"date":"2025-04-04","current":-0.412001,"twenty":-1.222554,"median":-0.427144,"eighty":-0.230579,"marketCap":5062450},{"date":"2025-04-11","current":-0.34827,"twenty":-1.206745,"median":-0.425678,"eighty":-0.230646,"marketCap":4279350},{"date":"2025-04-17","current":-0.313796,"twenty":-1.206188,"median":-0.424288,"eighty":-0.230646,"marketCap":3855760},{"date":"2025-04-25","current":-0.331475,"twenty":-1.20334,"median":-0.420249,"eighty":-0.230739,"marketCap":4072986},{"date":"2025-05-02","current":-0.362634,"twenty":-1.202663,"median":-0.417467,"eighty":-0.23157,"marketCap":4455846},{"date":"2025-05-09","current":-0.357993,"twenty":-1.201713,"median":-0.412752,"eighty":-0.231772,"marketCap":4398824},{"date":"2025-05-16","current":-0.376365,"twenty":-1.183743,"median":-0.412001,"eighty":-0.23252,"marketCap":4311934},{"date":"2025-05-23","current":-0.36404,"twenty":-1.169969,"median":-0.409847,"eighty":-0.232938,"marketCap":4170732},{"date":"2025-05-30","current":-0.407512,"twenty":-1.160628,"median":-0.409847,"eighty":-0.233154,"marketCap":4668782},{"date":"2025-06-06","current":-0.391924,"twenty":-1.092835,"median":-0.407512,"eighty":-0.233982,"marketCap":4490195},{"date":"2025-06-13","current":-0.408626,"twenty":-1.043818,"median":-0.408357,"eighty":-0.234546,"marketCap":4681538},{"date":"2025-06-20","current":-0.386413,"twenty":-1.033216,"median":-0.4078,"eighty":-0.2346,"marketCap":4427051},{"date":"2025-06-27","current":-0.326233,"twenty":-0.999401,"median":-0.40383,"eighty":-0.235484,"marketCap":3737577},{"date":"2025-07-03","current":-0.369656,"twenty":-0.950204,"median":-0.402187,"eighty":-0.236907,"marketCap":4235070},{"date":"2025-07-11","current":-0.400665,"twenty":-0.901581,"median":-0.401083,"eighty":-0.237303,"marketCap":4590331},{"date":"2025-07-18","current":-0.380234,"twenty":-0.896561,"median":-0.400887,"eighty":-0.237592,"marketCap":4356254},{"date":"2025-07-25","current":-0.389308,"twenty":-0.888698,"median":-0.399218,"eighty":-0.23889,"marketCap":4460217},{"date":"2025-08-01","current":-0.346941,"twenty":-0.876965,"median":-0.395265,"eighty":-0.239969,"marketCap":3974831},{"date":"2025-08-08","current":-0.354624,"twenty":-0.869371,"median":-0.394629,"eighty":-0.24016,"marketCap":4062856},{"date":"2025-08-15","current":-0.38338,"twenty":-0.868821,"median":-0.394151,"eighty":-0.240825,"marketCap":3959846},{"date":"2025-08-22","current":-0.351707,"twenty":-0.867543,"median":-0.393679,"eighty":-0.240825,"marketCap":3632698}],"updateTime":1756106302450},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DRMA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2561449785","title":"Dermata Therapeutics Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2561449785","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561449785?lang=en_us&edition=fundamental","pubTime":"2025-08-22 00:41","pubTimestamp":1755794460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DRMA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 21, 2025 12:41 ET (16:41 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","DRMA"],"gpt_icon":0},{"id":"2559846639","title":"Dermata Therapeutics Q2 EPS $(1.66) Beats $(2.90) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559846639","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559846639?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:09","pubTimestamp":1755119361,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Q2 EPS $(1.66) Beats $(2.90) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47108471/dermata-therapeutics-q2-eps-1-66-beats-2-90-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","DRMA"],"gpt_icon":0},{"id":"2559198439","title":"Dermata Therapeutics Announces Positive Results from XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2559198439","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559198439?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:01","pubTimestamp":1755118913,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc., a late-stage biotechnology company, recently announced the results of its XYNGARI Phase 3 Spongilla Treatment of Acne Research  clinical trial. The trial, focused on moderate-to-severe acne, met all three primary endpoints, demonstrating statistically significant results versus placebo at the study's conclusion. Results indicated that XYNGARI achieved significant separation from placebo after just four weeks of treatment, as well as at the 12-week primary endpoint required by the FDA. Following these positive results, Dermata has initiated additional manufacturing and is evaluating the next steps for the upcoming XYNGARI Phase 3 STAR-2 clinical trial, which will be followed by a 9-month extension study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL2L0rTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dermata Therapeutics Announces Positive Results from XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne Treatment","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DRMA","BK4007","BK4539"],"gpt_icon":0},{"id":"2556542338","title":"Dermata Therapeutics Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2556542338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556542338?lang=en_us&edition=fundamental","pubTime":"2025-08-01 07:50","pubTimestamp":1754005823,"startTime":"0","endTime":"0","summary":"19:50 EDT Dermata Therapeutics (DRMA) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","DRMA"],"gpt_icon":0},{"id":"2555804441","title":"Dermata Therapeutics Announces 1:10 Reverse Stock Split Effective August 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2555804441","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555804441?lang=en_us&edition=fundamental","pubTime":"2025-07-30 21:00","pubTimestamp":1753880441,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. has announced a one-for-10 reverse stock split of its common stock, effective August 1, 2025. The reverse split will consolidate every ten shares into one, with trading on a split-adjusted basis expected to commence on the Nasdaq Capital Market. The move will not alter the par value or authorized number of shares. Stockholders granted the board the discretion to implement the reverse split within a specified ratio range, with the board approving the final ratio. Fractional shares will be compensated with cash payments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDLw05FP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","DRMA","BK4007"],"gpt_icon":0},{"id":"2551914439","title":"Dermata Therapeutics Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2551914439","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551914439?lang=en_us&edition=fundamental","pubTime":"2025-07-16 18:01","pubTimestamp":1752660068,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on July 15, 2025. During the meeting, Mary Fisher and Andrew Sandler M.D. were elected as Class I directors. The appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The issuance of shares of the Company's common stock underlying certain warrants was approved. An amendment to effect a reverse stock split of the issued and outstanding shares of Common Stock was also approved. Additionally, the proposal to adjourn the meeting if there were insufficient votes to approve certain proposals was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. pu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL6Q8cSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4193","BK4139","BK4007","FPH","BK4539","DRMA"],"gpt_icon":0},{"id":"2549378547","title":"Dermata Therapeutics receives notice of grant of Australian patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2549378547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549378547?lang=en_us&edition=fundamental","pubTime":"2025-07-08 20:50","pubTimestamp":1751979059,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics (DRMA) announced the Australian Patent Office has granted its patent application for its DMT410 program for the treatment of h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-receives-notice-of-grant-of-australian-patent-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-receives-notice-of-grant-of-australian-patent-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","LENZ","DRMA"],"gpt_icon":0},{"id":"2549544620","title":"Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2549544620","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549544620?lang=en_us&edition=fundamental","pubTime":"2025-07-08 20:00","pubTimestamp":1751976052,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled \"Compositions for the treatment of skin conditions,\" is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the ori","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDLb3zG3H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2549356823","title":"Dermata Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2549356823","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549356823?lang=en_us&edition=fundamental","pubTime":"2025-07-08 05:26","pubTimestamp":1751923565,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. has announced a regulatory issue concerning its compliance with Nasdaq's listing requirements. On May 14, 2025, the company received a notice from Nasdaq indicating that its common stock had fallen below the minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550. In response, Dermata is seeking shareholder approval for a reverse stock split at its upcoming annual meeting on July 15, 2025, as part of its efforts to regain compliance. Nasdaq has granted Dermata an exception until August 14, 2025, to meet the required bid price. Failure to do so, or to meet other listing requirements, could result in the delisting of Dermata's securities from the Nasdaq Capital Market.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nNDL6p0lFM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","DRMA","BK4139"],"gpt_icon":0},{"id":"2542349716","title":"Dermata Therapeutics Inc. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2542349716","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542349716?lang=en_us&edition=fundamental","pubTime":"2025-06-11 00:51","pubTimestamp":1749574291,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. has released a corporate presentation highlighting their advancements in dermatology treatments. The company showcases their unique, multi-use topical platform technology targeting the large medical and aesthetic dermatology market. Key developments include Xyngari, a once-weekly topical treatment for acne, which has shown statistically significant results in the STAR-1 Phase 3 study. A second Phase 3 study, STAR-2, is slated to begin in 2025. Additionally, Dermata's program for psoriasis has completed a positive Phase 1b study, and their DMT410 product for hyperhidrosis is planning a Phase 2a trial with DAXXIFY following a successful Phase 1 proof-of-concept with BOTOX. The presentation also outlines the market opportunities within dermatology, including a prevalence of 50 million acne cases in the US alone, and a growing demand for hyperhidrosis treatments. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDLbsMj83:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2541074005","title":"Dermata Therapeutics Inc. Appoints Baker Tilly as New Certifying Accountant Following Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2541074005","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541074005?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:31","pubTimestamp":1749155515,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. has announced a change in its certifying accountants following the merger of Moss Adams LLP with Baker Tilly US, LLP, effective June 3, 2025. The audit committee of Dermata's Board of Directors has approved the appointment of Baker Tilly as the company's new independent registered public accounting firm, succeeding Moss Adams. The transition comes without any disagreements or reportable events regarding accounting principles or practices during the years 2023 and 2024, as well as the interim period through June 3, 2025. Moss Adams' audit reports for these years did not contain adverse opinions but included an explanatory paragraph about a going concern uncertainty.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL3ChLWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2537934477","title":"Dermata Therapeutics Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2537934477","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537934477?lang=en_us&edition=fundamental","pubTime":"2025-05-21 23:02","pubTimestamp":1747839720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DRMA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 21, 2025 11:02 ET (15:02 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","DRMA"],"gpt_icon":0},{"id":"2537936617","title":"Dermata Therapeutics Begins Manufacturing for STAR-2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2537936617","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537936617?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:31","pubTimestamp":1747834265,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics ( ($DRMA) ) has provided an update. On May 20, 2025, Dermata Therapeutics announced the initiation of manufacturing for the dr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-begins-manufacturing-for-star-2-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-begins-manufacturing-for-star-2-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","DRMA","LENZ"],"gpt_icon":0},{"id":"2537935715","title":"BRIEF-Dermata Therapeutics Inc - Potential NDA Filing For Xyngari In H1 2028 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537935715","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537935715?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:29","pubTimestamp":1747834155,"startTime":"0","endTime":"0","summary":"BRIEF-Dermata Therapeutics Inc - Potential NDA Filing For Xyngari In H1 2028 - SEC FilingMay 21  - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC - POTENTIAL NDA FILING FOR XYNGARI IN H1 2028 - SEC FILINGSource text: [ID:n0001641172-25-011873]Further company coverage: DRMA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nFWN3RT2V6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","DRMA","BK4139"],"gpt_icon":0},{"id":"2537933711","title":"Dermata Therapeutics Inc. Announces Initiation of Drug Manufacturing for XYNGARI™ Phase 3 STAR-2 Trial, Set to Begin in Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2537933711","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537933711?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:01","pubTimestamp":1747832465,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. Announces Initiation of Drug Manufacturing for XYNGARI Phase 3 STAR-2 Trial, Set to Begin in Q4 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL9XPnrJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","DRMA","BK4007"],"gpt_icon":0},{"id":"2536326202","title":"Dermata Faces Nasdaq Delisting Risk Over Bid Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2536326202","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536326202?lang=en_us&edition=fundamental","pubTime":"2025-05-17 05:51","pubTimestamp":1747432298,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics ( ($DRMA) ) has shared an announcement. On May 14, 2025, Dermata Therapeutics, Inc. announced that it had regained compliance ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dermata-faces-nasdaq-delisting-risk-over-bid-price?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dermata-faces-nasdaq-delisting-risk-over-bid-price?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQQ","BK4539","LU2210150020.SGD","BK4588","QLD","LU2095319765.USD","IE00BGHQF748.EUR","USJW.SI","BK4585","NVIW.SI","IE00BKPKM429.USD","DRMA","LU2210149790.SGD","IE00B3QW5Z07.USD","TSYW.SI","BK4112","IE00B64PRP62.GBP","BK4139","SQQQ","PSQ","BK4007",".IXIC","MNQmain","NQmain","NDAQ","QID","USAW.SI"],"gpt_icon":0},{"id":"2535879020","title":"Dermata Reports Positive Phase 3 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535879020","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535879020?lang=en_us&edition=fundamental","pubTime":"2025-05-14 21:30","pubTimestamp":1747229459,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics ( ($DRMA) ) just unveiled an update. In the first quarter of 2025, Dermata Therapeutics announced positive results from its XY...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dermata-reports-positive-phase-3-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dermata-reports-positive-phase-3-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRMA","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2535024146","title":"Dermata Therapeutics Announces Positive Phase 3 Trial Results, Reports $6.6M Cash Increase in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2535024146","media":"Reuters","labels":["productRelease","dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535024146?lang=en_us&edition=fundamental","pubTime":"2025-05-14 21:02","pubTimestamp":1747227744,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. reported positive topline results from its Phase 3 Spongilla Treatment of Acne Research  clinical trial, achieving all co-primary endpoints. The company also entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY for the treatment of axillary hyperhidrosis. Financial results for the first quarter of 2025 show that as of March 31, the company had $9.7 million in cash and cash equivalents, an increase from $3.2 million as of December 31, 2024. This increase was due to approximately $8.5 million of financing proceeds, offset by $1.9 million of cash used in operations. Research and development expenses were $1.3 million for the quarter ended March 31, 2025, a decrease from $1.6 million for the same period in 2024, primarily due to decreased clinical trial expenses and stock-based compensation reductions. Dermata expects its current cash resources to fund operations into the first quarter of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL49vvVM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Dermata Therapeutics Announces Positive Phase 3 Trial Results, Reports $6.6M Cash Increase in Q1 2025","news_tag":"productRelease,dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DRMA","BK4139","BK4539"],"gpt_icon":0},{"id":"2532778260","title":"Press Release: California Water Service Group Reports First Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532778260","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532778260?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:00","pubTimestamp":1746104400,"startTime":"0","endTime":"0","summary":"SAN JOSE, Calif., May 01, 2025  -- California Water Service Group , a leading publicly traded water utility serving California, Hawaii, New Mexico, Washington, and Texas, today reported financial results for the first quarter 2025.-- The inclusion of both GAAP and non-GAAP financial measures for 2024 to. assist investors in comparing 2024 and 2025 performance.-- Net income attributable to Group of $13.3 million, or $0.22 per diluted. share, a decrease of $56.6 million and $0.99 per share, respectively,compared to the same period in the prior year. However, Q1 2025 net. income and diluted earnings per share increased by $9.2 million and. The Company encourages stockholders and other interested parties to assess first quarter 2025 results as compared to first quarter 2024 results factoring in the significant benefit of 2023 interim rate relief from the delayed 2021 California GRC decision as discussed below.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CWT","BK4539","BK4172","BK4007","DRMA","BK4139"],"gpt_icon":0},{"id":"2527127864","title":"Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2527127864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527127864?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:36","pubTimestamp":1744724164,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics (DRMA) announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI had a statisticall...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermatas-xyngari-trial-hits-statistically-significant-difference-at-4-weeks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermatas-xyngari-trial-hits-statistically-significant-difference-at-4-weeks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","DRMA","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}